These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6848891)

  • 1. Thymectomy in multiple sclerosis. Two preliminary trials.
    Ferguson TB; Clifford DB; Montgomery EB; Bruns KA; McGregor PJ; Trotter JL
    J Thorac Cardiovasc Surg; 1983 Jan; 85(1):88-93. PubMed ID: 6848891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymectomy-induced decrease in T gamma cells and OKT8+ cells in multiple sclerosis.
    Trotter JL; Gebel HM; Ferguson TB; Garvey WF; Rodey GE
    Ann Neurol; 1983 Dec; 14(6):656-61. PubMed ID: 6228189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up].
    Lhermitte F; Marteau R; de Saxcé H
    Rev Neurol (Paris); 1987; 143(2):98-107. PubMed ID: 3299618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical trial of cyclosporine in multiple sclerosis: the pros.
    Dommasch D
    Neurology; 1988 Jul; 38(7 Suppl 2):28-9. PubMed ID: 3290711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH
    Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
    Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V
    N Engl J Med; 1987 Aug; 317(7):408-14. PubMed ID: 3302705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionality or aesthetics? A pilot study of music therapy in the treatment of multiple sclerosis patients.
    Aldridge D; Schmid W; Kaeder M; Schmidt C; Ostermann T
    Complement Ther Med; 2005 Mar; 13(1):25-33. PubMed ID: 15907675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience].
    Lhermitte F; Marteau R; Roullet E; de Saxcé H; Loridan M
    Rev Neurol (Paris); 1984; 140(10):553-8. PubMed ID: 6438761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].
    Trouillas P; Neuschwander P; Nighoghossian N; Adeleine P; Tremisi P
    Rev Neurol (Paris); 1989; 145(5):369-77. PubMed ID: 2662340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with azathioprine: the pros.
    Ellison GW; Myers LW; Mickey MR; Graves MC; Tourtellotte WW; Nuwer MR
    Neurology; 1988 Jul; 38(7 Suppl 2):20-3. PubMed ID: 3290709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term immunosuppression in multiple sclerosis: evaluation of treatments begun before 1972].
    Sabouraud O; Oger J; Darcel F; Madigand M; Merienne M
    Rev Neurol (Paris); 1984; 140(2):125-30. PubMed ID: 6710012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment.
    Werneck LC; Cunha FM; Scola RH
    Acta Neurol Scand; 2000 Jan; 101(1):41-6. PubMed ID: 10660151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot-study on large-dose alternate-day steroid therapy in multiple sclerosis.
    Cendrowski WS
    Schweiz Arch Neurol Neurochir Psychiatr; 1975; 117(2):197-203. PubMed ID: 1224185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive treatment of multiple sclerosis. 4. Results of treatment with azathioprine and antilymphocyte globulin (author's transl)].
    Frick E; Angstwurm H; Blomer R; Strauss G
    MMW Munch Med Wochenschr; 1977 Sep; 119(35):1111-4. PubMed ID: 408666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine and multiple sclerosis: the cons.
    Rudge P
    Neurology; 1988 Jul; 38(7 Suppl 2):29-30. PubMed ID: 3290712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.